JP5512534B2 - 骨塩密度関連の疾患の治療および診断の方法 - Google Patents

骨塩密度関連の疾患の治療および診断の方法 Download PDF

Info

Publication number
JP5512534B2
JP5512534B2 JP2010536471A JP2010536471A JP5512534B2 JP 5512534 B2 JP5512534 B2 JP 5512534B2 JP 2010536471 A JP2010536471 A JP 2010536471A JP 2010536471 A JP2010536471 A JP 2010536471A JP 5512534 B2 JP5512534 B2 JP 5512534B2
Authority
JP
Japan
Prior art keywords
tbxas1
acid
mineral density
txas
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010536471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507491A5 (enExample
JP2011507491A (ja
Inventor
ヴァレリー コルミエール−デイル、
アルノルド ミュニック、
Original Assignee
アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） filed Critical アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル）
Publication of JP2011507491A publication Critical patent/JP2011507491A/ja
Publication of JP2011507491A5 publication Critical patent/JP2011507491A5/ja
Application granted granted Critical
Publication of JP5512534B2 publication Critical patent/JP5512534B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/52—Isomerases (5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
    • C12Y503/99005—Thromboxane-A synthase (5.3.99.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010536471A 2007-12-07 2008-12-05 骨塩密度関連の疾患の治療および診断の方法 Expired - Fee Related JP5512534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301643 2007-12-07
EP07301643.8 2007-12-07
PCT/EP2008/066880 WO2009071661A1 (en) 2007-12-07 2008-12-05 Methods for the treatment and diagnosis of bone mineral density related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013254555A Division JP2014110788A (ja) 2007-12-07 2013-12-09 骨塩密度関連の疾患の治療および診断の方法

Publications (3)

Publication Number Publication Date
JP2011507491A JP2011507491A (ja) 2011-03-10
JP2011507491A5 JP2011507491A5 (enExample) 2011-11-24
JP5512534B2 true JP5512534B2 (ja) 2014-06-04

Family

ID=39142026

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010536471A Expired - Fee Related JP5512534B2 (ja) 2007-12-07 2008-12-05 骨塩密度関連の疾患の治療および診断の方法
JP2013254555A Pending JP2014110788A (ja) 2007-12-07 2013-12-09 骨塩密度関連の疾患の治療および診断の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013254555A Pending JP2014110788A (ja) 2007-12-07 2013-12-09 骨塩密度関連の疾患の治療および診断の方法

Country Status (5)

Country Link
US (2) US20100284991A1 (enExample)
EP (1) EP2227560B1 (enExample)
JP (2) JP5512534B2 (enExample)
ES (1) ES2655209T3 (enExample)
WO (1) WO2009071661A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655209T3 (es) 2007-12-07 2018-02-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea
KR102845511B1 (ko) * 2019-02-08 2025-08-12 삼성디스플레이 주식회사 축합환 화합물 및 이를 포함한 유기 발광 소자

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN445095A0 (en) * 1995-07-27 1995-08-17 Garvan Institute Of Medical Research Method of predicting bone density
CA2602374A1 (en) * 2005-03-23 2006-09-28 Boehringer Ingelheim International Gmbh Composition comprising a combined thromboxane receptor antagonist and thromboxane synthase inhibitor and a cox-2 inhibitor
MX2009003761A (es) * 2006-10-04 2009-06-30 Schering Corp Derivados biciclicos y triciclicos como antagonistas del receptor de trombina.
ES2655209T3 (es) 2007-12-07 2018-02-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Métodos para el tratamiento y diagnóstico de enfermedades relacionadas con la densidad mineral ósea

Also Published As

Publication number Publication date
JP2014110788A (ja) 2014-06-19
EP2227560B1 (en) 2017-10-18
EP2227560A1 (en) 2010-09-15
WO2009071661A1 (en) 2009-06-11
US20150104437A1 (en) 2015-04-16
JP2011507491A (ja) 2011-03-10
ES2655209T3 (es) 2018-02-19
US9834820B2 (en) 2017-12-05
US20100284991A1 (en) 2010-11-11

Similar Documents

Publication Publication Date Title
AU2013273242B2 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
JP6381519B2 (ja) がん転移の予後診断および処置のための方法
CA2588270A1 (en) Methods and compositions for treating ocular disorders
JP4354633B2 (ja) 低酸素調節性遺伝子
AU2016248317A1 (en) Methods for treating myeloproliferative disorders
JP2003520780A (ja) Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
Roubeix et al. Splenic monocytes drive pathogenic subretinal inflammation in age-related macular degeneration
Xu et al. NCF4 regulates antigen presentation of cysteine peptides by intracellular oxidative response and restricts activation of autoreactive and arthritogenic T cells
Furuyama et al. Genotypic Effect of ABCG1 Gene Promoter—257T> G Polymorphism on Coronary Artery Disease Severity in Japanese Men
US10059946B2 (en) Method for treatment of heart failure
US9834820B2 (en) Methods for the treatment and diagnosis of bone mineral density related diseases
US20080318241A1 (en) Methods and Systems for Detecting Antiangiogenesis
JP5737721B2 (ja) Ｈｔｒａ１変異と家族性虚血性脳小血管病との関連
JP2007538003A (ja) 心筋梗塞、脳卒中および末梢動脈閉塞疾患に対する感受性遺伝子、治療の方法
US6544743B1 (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
WO2003006687A2 (en) Novel target genes for diseases of the heart
US20190185852A1 (en) Therapeutically modulating apob and apoai
JP2008508857A (ja) 本態性振顫の診断及び治療
JP2011508730A (ja) Ｕｄｐ−ｎ−アセチル−アルファ−ｄ−ガラクトサミン：ポリペプチドｎ−アセチルガラクトサミニルトランスフェラーゼ（ｇａｌｎｔ）モジュレーションによる高比重リポタンパク質レベルの改変
JP2010502985A (ja) インスリン感受性の制御におけるリポカリン２の使用
WO2011039650A1 (en) Method for the diagnosis/prognosis of age-related macular degeneration
Galyan et al. Fragment-based virtual screening identifies a rst-in-class preclinical drug candidate for Huntington’s
EP2167969A2 (en) Detecting and controlling abnormal hematopoiesis
JP2009515900A (ja) 血清応答因子及びミオカルディンは脳アミロイドアンギオパチーを制御する
HK1113690B (en) Methods and compositions for diagnosing age-related macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140326

R150 Certificate of patent or registration of utility model

Ref document number: 5512534

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees